Drug Trial Radar · NCT01920061
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Last checked: Nov 19, 2026Latest source record: Sep 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
Sep 10, 2013
Primary completion
Jan 8, 2020
Study completion Jan 8, 2020
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).
Conditions
- Neoplasm
Interventions
PF-05212384 (gedatolisib)Drug
PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
DocetaxelDrug
Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
CisplatinDrug
Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
DacomitinibDrug
Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and CTime frame: Up to 21 days
- Percentage of Participants With Objective Response - Arm B ExpansionTime frame: Cycle 1 Day 1 up to 18 months
Locations
29 sites in 5 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
Ronald Reagan UCLA Medical Center
Los Angeles, California
UCLA Hematology Oncology
Los Angeles, California
Westwood Bowyer Clinic
Los Angeles, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Santa Monica UCLA Medical Center & Orthopaedic Hospital
Santa Monica, California
UCLA Hematology Oncology
Santa Monica, California
University of Colorado Denver CTO (CTRC)
Aurora, Colorado
University of Colorado Hospital
Aurora, Colorado
Brigham and Women's Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Harper Professional Building
Detroit, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Medical University of South Carolina/ University Hospital
Charleston, South Carolina
Medical University of South Carolina
Charleston, South Carolina
MUSC SCTR Research
Charleston, South Carolina
MUSC Health East Cooper
Mt. Pleasant, South Carolina
MUSC Specialty Care-North
North Charleston, South Carolina
British Columbia Cancer Agency - Vancouver Centre
Vancouver, British Columbia, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Istituto Europeo di Oncologia - Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative
Milan, MI, Italy
Istituto Regina Elena Struttura Complessa Oncologia Medica A
Roma, RM, Italy
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
University College London Hospital, NIHR UCLH Clinical Research Facility
London, United Kingdom
Oxford Cancer Centre
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.